6533b82afe1ef96bd128b666
RESEARCH PRODUCT
FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.
Andrew WotherspoonSusana Rosello KeranenClare PeckittJanet ThomasIan ChauGina BrownDavid CunninghamDavid Gonzalez De CastroBengt GlimeliusDiana TaitFrancesco SclafaniSanna Hulkki WilsonJaume CapdevilaRuwaida BegumJacqueline Oatessubject
OncologyCancer Researchmedicine.medical_specialtyCetuximabmedicine.drug_classColorectal cancerbusiness.industrySingle-nucleotide polymorphismBioinformaticsMonoclonal antibodymedicine.diseasedigestive system diseasesOncologyInternal medicinemedicinebusinessmedicine.drugdescription
3573 Background: FCγRIIa-H131R and FCγRIIIa-V158F SNPs have been reported to enhance the immune-mediated effects of monoclonal antibodies including cetuximab (C) in metastatic colorectal cancer (CR...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |